Almotriptan interactions
Full monograph for AlmotriptanCheck it against another medicine
Medicines
185 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Amitriptyline Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 99 sources — open the full entry |
| Amitriptyline Hydrochloride + Chlordiazepoxide | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 99 sources — open the full entry |
| Bromocriptine Mesylate | Major | Synergy | Coadministration of two or more 5-HT1 receptor agonists and/or ergotamine-containing or ergot-type medications may potentiate the risk of vasospastic… | 73 sources — open the full entry |
| Cabergoline | Major | Synergy | Coadministration of two or more 5-HT1 receptor agonists and/or ergotamine-containing or ergot-type medications may potentiate the risk of vasospastic… | 73 sources — open the full entry |
| Citalopram Hydrobromide | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Clomipramine Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 99 sources — open the full entry |
| Desvenlafaxine Succinate | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Dextromethorphan + Bupropion | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 99 sources — open the full entry |
| Dextromethorphan + Phenylephrine + Triprolidine | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 99 sources — open the full entry |
| Dextromethorphan + Pseudoephedrine + Triprolidine | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 99 sources — open the full entry |
| Dextromethorphan Hydrobromide | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 99 sources — open the full entry |
| Dextromethorphan Hydrobromide + Guaifenesin | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 99 sources — open the full entry |
| Dextromethorphan Polistirex | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 99 sources — open the full entry |
| Diphenhydramine + Dextromethorphan + Levomenthol | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 99 sources — open the full entry |
| Doxepin (Oral) | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 99 sources — open the full entry |
| Doxepin (Topical) | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 99 sources — open the full entry |
| Duloxetine Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Ergometrine Maleate | Major | Synergy | Coadministration of two or more 5-HT1 receptor agonists and/or ergotamine-containing or ergot-type medications may potentiate the risk of vasospastic… | 73 sources — open the full entry |
| Escitalopram Oxalate | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Fentanyl Citrate | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Fluoxetine Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Fluvoxamine Maleate | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Granisetron | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Guaifenesin + Dextromethorphan + Menthol | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 99 sources — open the full entry |
| Imipramine Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 99 sources — open the full entry |
| Lasmiditan Hemisuccinate | Major | Synergy | Coadministration of lasmiditan and serotonergic agents may increase the risk of serotonin syndrome. Lasmiditan binds to the 5-HT(1F) receptor, where it… | 5 sources — open the full entry |
| Levomilnacipran Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Linezolid | Major | Synergy | Coadministration of linezolid with serotonergic agents may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal… | 52 sources — open the full entry |
| Maprotiline Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 99 sources — open the full entry |
| Methylergonovine Maleate | Major | Synergy | Coadministration of two or more 5-HT1 receptor agonists and/or ergotamine-containing or ergot-type medications may potentiate the risk of vasospastic… | 73 sources — open the full entry |
| Milnacipran Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 102 sources — open the full entry |
| Mirtazapine | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Ondansetron | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Palonosetron | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Paracetamol + Tramadol Hydrochloride | Major | Synergy · Unknown | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…2 documented mechanisms | 100 sources — open the full entry |
| Paroxetine Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Pentazocine | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 99 sources — open the full entry |
| Pethidine Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 99 sources — open the full entry |
| Remifentanil Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 99 sources — open the full entry |
| Rizatriptan Benzoate | Major | Synergy | Coadministration of two or more 5-HT1 receptor agonists and/or ergotamine-containing or ergot-type medications may potentiate the risk of vasospastic… | 73 sources — open the full entry |
| Sertraline Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Sumatriptan | Major | Synergy | Coadministration of two or more 5-HT1 receptor agonists and/or ergotamine-containing or ergot-type medications may potentiate the risk of vasospastic… | 73 sources — open the full entry |
| Tapentadol Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Tramadol Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Venlafaxine Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Vilazodone Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Vortioxetine Hydrobromide | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Zolmitriptan | Major | Synergy | Coadministration of two or more 5-HT1 receptor agonists and/or ergotamine-containing or ergot-type medications may potentiate the risk of vasospastic… | 73 sources — open the full entry |
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
| Aprepitant | Moderate | Metabolism | Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4… | 2 sources — open the full entry |
Conditions
Conditions in which Almotriptan needs care, as documented in this source.
Cardiovascular Diseases
MajorThe use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases. In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension. 5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia. Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD). Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance. Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities. However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.
23 sources
- Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992): 1415
- Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993): 1185
- Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992): d713-4
- Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993): 861-2
- MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993): 1092
- Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994): 1105-6
- "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome (2001):
- Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994): 622-51
Show all 23 sourcesShow fewer sources
- Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994): 1704-5
- Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994): 305-9
- Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995): 1211-3
- Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996): 329-31
- Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996): 46-51
- Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996): 554-9
- "Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals (2001):
- "Product Information. Amerge (naratriptan)." Glaxo Wellcome (2001):
- "Product Information. Maxalt (rizatriptan)." Merck & Co., Inc (2001):
- Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999): 704-11
- Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999): 699-723
- Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000): 275
- "Product Information. Axert (almotriptan)." Pharmacia and Upjohn (2001):
- "Product Information. Frova (frovatriptan)." Endo Laboratories LLC (2001):
- "Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals (2003):
Coronary Artery Disease
MajorThe group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia. Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD). Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance. In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease. As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur. Periodic cardiovascular evaluations should be performed during intermittent, long-term use.
23 sources
- Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992): 1415
- Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993): 1185
- Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992): d713-4
- Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993): 861-2
- MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993): 1092
- Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994): 1105-6
- "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome (2001):
- Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994): 622-51
Show all 23 sourcesShow fewer sources
- Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994): 1704-5
- Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994): 305-9
- Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995): 1211-3
- Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996): 329-31
- Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996): 46-51
- Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996): 554-9
- "Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals (2001):
- "Product Information. Amerge (naratriptan)." Glaxo Wellcome (2001):
- "Product Information. Maxalt (rizatriptan)." Merck & Co., Inc (2001):
- Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999): 704-11
- Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999): 699-723
- Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000): 275
- "Product Information. Axert (almotriptan)." Pharmacia and Upjohn (2001):
- "Product Information. Frova (frovatriptan)." Endo Laboratories LLC (2001):
- "Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals (2003):
Kidney Diseases
MajorApproximately 40% of an administered dose of almotriptan is excreted unchanged in the urine. Following oral administration in patients with renal impairment, the clearance of almotriptan was approximately 65% lower in patients with severe impairment (CrCl = 10 to 30 mL/min) and 40% lower in patients with moderate impairment (CrCl = 31 to 71 mL/min) compared to healthy controls. Peak plasma concentrations of almotriptan increased by approximately 80% in these patients. The manufacturer recommends that a starting dose of 6.25 mg be used in patients with significantly impaired renal function, and that the maximum dosage not exceed 12.5 mg per 24-hour period.
1 source
- "Product Information. Axert (almotriptan)." Pharmacia and Upjohn (2001):
Liver Diseases
MajorAlmotriptan is partially metabolized by the liver. The pharmacokinetics of almotriptan have not been assessed in patients with hepatic impairment. Based on the known mechanisms of clearance of almotriptan, the maximum decrease in clearance expected due to hepatic impairment would be 60%. The manufacturer recommends that a starting dose of 6.25 mg be used in patients with significantly impaired hepatic function, and that the maximum dosage not exceed 12.5 mg per 24-hour period.
1 source
- "Product Information. Axert (almotriptan)." Pharmacia and Upjohn (2001):
Therapeutic duplication
Drug classes that overlap with Almotriptan, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
ergot-like drugs
The recommended maximum number of medicines in the 'ergot-like drugs' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'ergot-like drugs' category.
Example product in the source data (US market): Treximet
ergot-like drugs
The recommended maximum number of medicines in the 'ergot-like drugs' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'ergot-like drugs' category.
Example product in the source data (US market): Migergot